Form 4: Collegium Pharmaceutical Executive Scott Dreyer Sells Shares Under 10b5-1 Plan

EVP & Chief Commercial Officer of Collegium Pharmaceutical, Scott Dreyer, sold shares of common stock on February 26, 2024, under a pre-arranged 10b5-1 trading plan.

Summary

• Scott Dreyer, EVP & Chief Commercial Officer of Collegium Pharmaceutical, sold shares of the company's common stock on February 26, 2024.
• The sales were executed under a Rule 10b5-1 trading plan adopted on August 9, 2023.
• A total of 10,000 shares were sold in two transactions at weighted average prices of $36.3754 and $37.153.
• Following the reported transactions, Dreyer beneficially owns 138,918 shares of Collegium Pharmaceutical.
• The sales were conducted in multiple transactions within price ranges of $35.96 to $36.95 and $37.01 to $37.50.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing related to stock sales by an executive. It doesn't inherently convey positive or negative sentiment, as it's a routine disclosure.

Industry Context

Executive stock sales are a common occurrence and are often pre-planned to avoid accusations of insider trading. The use of a 10b5-1 plan allows insiders to sell shares at predetermined times and prices.

Stakeholder Impact

• The stock sale may have a minor impact on shareholders, potentially creating slight downward pressure on the stock price in the short term.

Key Dates